Ryvu Therapeutics has dosed the first patient in the JASPIS-01 Phase II trial evaluating dapolsertib as both monotherapy and in combination with glofitamab for relapsed/refractory diffuse large B-cell lymphoma.
Ryvu Therapeutics reported USD 18.6 million in operating revenues for Q1-Q3 2024, compared to USD 11.9 million in the same period last year, driven by pipeline advancements.
Ryvu Therapeutics will showcase clinical data for RVU120, their CDK8/19 inhibitor, demonstrating efficacy in 15 of 29 evaluable AML and HR-MDS patients, including complete remission in a patient with NPM1 and DNMT3A mutations.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.